ConductScience.org, home

Paper40323013

APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer.

Garcia NMG and 7 others. Cancer Res Commun, 2025. Cited by 13 papers, by iCite.

Cite this record

ConductScience Library. APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer. Papers, record 40323013. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40323013

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer.
PubMed
Journal
Cancer Res Commun
PubMed
Year
2025
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
13
iCite
Relative citation ratio, by iCite
2.99, provisional
iCite
Revised in PubMed
2026-07-16
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Drug Resistance, NeoplasmMajor topic
Lung NeoplasmsMajor topic
Cytidine DeaminaseMajor topic
Protein Kinase InhibitorsMajor topic
Carcinoma, Non-Small-Cell LungMajor topic
Minor Histocompatibility AntigensMajor topic
Humans
ErbB Receptors
Cell Line, Tumor
Gefitinib
Mutation
Cell Survival
Gene Expression Regulation, Neoplastic
APOBEC Deaminases

Source PubMed

Download CSV of topics

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P30 CA015704NCI NIH HHSUnited StatesP30CA015704PubMed and NIHNIH RePORTER
R01 CA208042NCI NIH HHSUnited StatesR01CA208042PubMed and NIHNIH RePORTER
R01 CA285322NCI NIH HHSUnited StatesR01CA285322PubMed and NIHNIH RePORTER

Download CSV of grants

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Update of37461590

Source PubMed

Download CSV of comments and corrections

References83

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127730215The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer.Sci Adv2016https://conductscience.org/library/papers/27730215PubMed
222407829Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities.Clin Cancer Res2012https://conductscience.org/library/papers/22407829PubMed
325661795Transformation to a squamous cell carcinoma phenotype of an EGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine kinase inhibitor.J Clin Pathol2015https://conductscience.org/library/papers/25661795PubMed
418093943MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.Proc Natl Acad Sci U S A2007https://conductscience.org/library/papers/18093943PubMed
526537451Recombinase-based conditional and reversible gene regulation via XTR alleles.Nat Commun2015https://conductscience.org/library/papers/26537451PubMed
619692680Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.N Engl J Med2009https://conductscience.org/library/papers/19692680PubMed
726799287Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA.Oncotarget2017https://conductscience.org/library/papers/26799287PubMed
828787442Comparative transcriptomes of adenocarcinomas and squamous cell carcinomas reveal molecular similarities that span classical anatomic boundaries.PLoS Genet2017https://conductscience.org/library/papers/28787442PubMed
928284717Evidence, Mechanism, and Clinical Relevance of the Transdifferentiation from Lung Adenocarcinoma to Squamous Cell Carcinoma.Am J Pathol2017https://conductscience.org/library/papers/28284717PubMed
1033947663Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution.Cancer Discov2021https://conductscience.org/library/papers/33947663PubMed
1131228622Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.J Thorac Oncol2019https://conductscience.org/library/papers/31228622PubMed
1226221054Maintaining epithelial stemness with p63.Sci Signal2015https://conductscience.org/library/papers/26221054PubMed
1325555954Histologic evolution from adenocarcinoma to squamous cell carcinoma after gefitinib treatment.Ann Thorac Surg2015https://conductscience.org/library/papers/25555954PubMed
1433750895Epiregulin confers EGFR-TKI resistance via EGFR/ErbB2 heterodimer in non-small cell lung cancer.Oncogene2021https://conductscience.org/library/papers/33750895PubMed
1531681582EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies.Front Oncol2019https://conductscience.org/library/papers/31681582PubMed
1624893891AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.Cancer Discov2014https://conductscience.org/library/papers/24893891PubMed
1717699786Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line.Cancer Res2007https://conductscience.org/library/papers/17699786PubMed
1838049664The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.Nat Genet2024https://conductscience.org/library/papers/38049664PubMed
1928445112Tracking the Evolution of Non-Small-Cell Lung Cancer.N Engl J Med2017https://conductscience.org/library/papers/28445112PubMed
2020371346A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations.Cell2010https://conductscience.org/library/papers/20371346PubMed

See all 83 referencesDownload CSV of references

Cited by12

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.

PMIDTitleJournalYearIn PapersSource
42898467Cellular memory after cancer therapy: persistence after drug withdrawal, maintenance across cell divisions, and responses to rechallenge.Front Pharmacol2026https://conductscience.org/library/papers/42898467PubMed
42535079Association of APOBEC mutagenesis with stromal and endothelial niche remodeling and PCDH9-linked signaling alterations in colorectal cancer.Front Immunol2026https://conductscience.org/library/papers/42535079PubMed
42427788Collapsing retroviruses for efficient delivery of viro-toxic cargoes.bioRxiv2026https://conductscience.org/library/papers/42427788PubMed
41675410Differential effects on tumor progression by APOBEC3A, APOBEC3B, and APOBEC3H Haplotype I in a breast cancer mouse xenograft model.Front Genet2025https://conductscience.org/library/papers/41675410PubMed
41501001APOBEC3C coordinates DDX5 in R-loop resolution and dynamic control of Chk1-mediated stress-responsive circuitry as a prerequisite for gemcitabine resistance in p53-deficient cells.Cell Death Dis2026https://conductscience.org/library/papers/41501001PubMed
41162355BRCA2 deficiency and replication stress drive APOBEC3-Mediated genomic instability.Nat Commun2025https://conductscience.org/library/papers/41162355PubMed
40781226Activation of APOBEC3 cytidine deaminases and endogenous retroviruses is integrated by MUC1-C in NSCLC cells.Cell Death Discov2025https://conductscience.org/library/papers/40781226PubMed
39138145Drug tolerant persister cell plasticity in cancer: A revolutionary strategy for more effective anticancer therapies.Signal Transduct Target Ther2024https://conductscience.org/library/papers/39138145PubMed
39047499Regulation, functional impact, and therapeutic targeting of APOBEC3A in cancer.DNA Repair (Amst)2024https://conductscience.org/library/papers/39047499PubMed
38473364Induction of Multiple Alternative Mitogenic Signaling Pathways Accompanies the Emergence of Drug-Tolerant Cancer Cells.Cancers (Basel)2024https://conductscience.org/library/papers/38473364PubMed
38254863APOBEC Mutagenesis in Cancer Development and Susceptibility.Cancers (Basel)2024https://conductscience.org/library/papers/38254863PubMed
38049664The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.Nat Genet2024https://conductscience.org/library/papers/38049664PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
APOBEC3B9582PubTator's text mininghttps://conductscience.org/library/genes/9582NCBI Gene
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
TP638626PubTator's text mininghttps://conductscience.org/library/genes/8626NCBI Gene

Download CSV of genes

Data1

The data bank entries PubMed's record names. Trial numbers are under Trials.

Data bankAccession
BioProjectPRJNA1235703

Source BioProject

Download CSV of data

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Drugs

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40323013

GET https://conductscience.org/api/papers/v1/40323013/references?page=2